BRPI0807095A2 - Antígenos recombinantes de citomegalovírus humano (hcmv) - Google Patents
Antígenos recombinantes de citomegalovírus humano (hcmv)Info
- Publication number
- BRPI0807095A2 BRPI0807095A2 BRPI0807095-4A2A BRPI0807095A BRPI0807095A2 BR PI0807095 A2 BRPI0807095 A2 BR PI0807095A2 BR PI0807095 A BRPI0807095 A BR PI0807095A BR PI0807095 A2 BRPI0807095 A2 BR PI0807095A2
- Authority
- BR
- Brazil
- Prior art keywords
- hcmv
- human cytomegalovirus
- recombinant antigens
- antigens
- recombinant
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/04—Varicella-zoster virus
- G01N2333/045—Cytomegalovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07101864 | 2007-02-07 | ||
| PCT/EP2008/000876 WO2008095677A1 (en) | 2007-02-07 | 2008-02-05 | Recombinant antigens of human cytomegalovirus (hcmv) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0807095A2 true BRPI0807095A2 (pt) | 2014-04-22 |
Family
ID=38229391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0807095-4A2A BRPI0807095A2 (pt) | 2007-02-07 | 2008-02-05 | Antígenos recombinantes de citomegalovírus humano (hcmv) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100068229A1 (enExample) |
| EP (1) | EP2114991A1 (enExample) |
| JP (1) | JP2010517544A (enExample) |
| KR (1) | KR20090126256A (enExample) |
| CN (1) | CN101605808A (enExample) |
| AU (1) | AU2008213356A1 (enExample) |
| BR (1) | BRPI0807095A2 (enExample) |
| CA (1) | CA2677455A1 (enExample) |
| EA (1) | EA200970731A1 (enExample) |
| IL (1) | IL200187A0 (enExample) |
| MX (1) | MX2009008248A (enExample) |
| SG (1) | SG178761A1 (enExample) |
| WO (1) | WO2008095677A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012015523A2 (pt) | 2009-12-23 | 2017-04-18 | 4-Antibody Ag | membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv. |
| JP5712513B2 (ja) * | 2010-07-07 | 2015-05-07 | 富士レビオ株式会社 | ヒトサイトメガロウイルス感染の検出方法 |
| AU2012207454B2 (en) * | 2011-01-18 | 2016-11-17 | Prionics Ag | Methods for amplification and detection of prions |
| CN102816246B (zh) * | 2012-09-04 | 2014-07-23 | 成都蓉生药业有限责任公司 | 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途 |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11174322B2 (en) | 2017-07-24 | 2021-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat HCMV related diseases |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL60184A (en) * | 1979-05-31 | 1984-05-31 | Schering Ag | Process for the specific cleavage of protein sequences from proteins |
| JPH01125328A (ja) * | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
| CA2050425A1 (en) * | 1990-09-03 | 1992-03-04 | Yoshiaki Uda | Pharmaceutical composition and its mucous use |
| SG48365A1 (en) * | 1992-05-23 | 1998-04-17 | Smithkline Beecham Biolog | Combined vaccines comprising hepatitis b surface antigen and other antigens |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| DK0960336T3 (da) * | 1996-07-12 | 2003-02-10 | Organon Teknika Bv | Peptidreagens til påvisning af humant cytomelagovirus (CMV) |
| US6306404B1 (en) * | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| AT408615B (de) * | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| WO2003010198A1 (en) | 2001-07-26 | 2003-02-06 | Kenton Srl | Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques |
-
2008
- 2008-02-05 SG SG2012008769A patent/SG178761A1/en unknown
- 2008-02-05 JP JP2009548617A patent/JP2010517544A/ja active Pending
- 2008-02-05 US US12/525,800 patent/US20100068229A1/en not_active Abandoned
- 2008-02-05 BR BRPI0807095-4A2A patent/BRPI0807095A2/pt not_active IP Right Cessation
- 2008-02-05 CA CA002677455A patent/CA2677455A1/en not_active Abandoned
- 2008-02-05 EP EP08707547A patent/EP2114991A1/en not_active Withdrawn
- 2008-02-05 AU AU2008213356A patent/AU2008213356A1/en not_active Abandoned
- 2008-02-05 WO PCT/EP2008/000876 patent/WO2008095677A1/en not_active Ceased
- 2008-02-05 MX MX2009008248A patent/MX2009008248A/es not_active Application Discontinuation
- 2008-02-05 EA EA200970731A patent/EA200970731A1/ru unknown
- 2008-02-05 KR KR1020097018587A patent/KR20090126256A/ko not_active Withdrawn
- 2008-02-05 CN CNA2008800045081A patent/CN101605808A/zh active Pending
-
2009
- 2009-07-30 IL IL200187A patent/IL200187A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090126256A (ko) | 2009-12-08 |
| IL200187A0 (en) | 2010-04-15 |
| MX2009008248A (es) | 2009-08-12 |
| AU2008213356A1 (en) | 2008-08-14 |
| US20100068229A1 (en) | 2010-03-18 |
| EA200970731A1 (ru) | 2010-02-26 |
| JP2010517544A (ja) | 2010-05-27 |
| CA2677455A1 (en) | 2008-08-14 |
| WO2008095677A1 (en) | 2008-08-14 |
| SG178761A1 (en) | 2012-03-29 |
| EP2114991A1 (en) | 2009-11-11 |
| CN101605808A (zh) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238421A (en) | Antibodies that neutralize and utilize human cytomegalovirus gb protein | |
| BRPI0807095A2 (pt) | Antígenos recombinantes de citomegalovírus humano (hcmv) | |
| EP2222710A4 (en) | RECOMBINANT RSV ANTIGEN | |
| DK1996292T3 (da) | Anvendelse af peptider til bekæmpelse af stråleskade | |
| EP2519249A4 (en) | METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE | |
| DK2356151T3 (da) | Human-antistoffer med høj affinitet for human IL-4 receptor | |
| DK3333188T3 (da) | Anti-NGF-antistoffer og deres anvendelse | |
| HUE037227T2 (hu) | Rekombináns HCMV és RHCMV vektorok és alkalmazásuk | |
| EP2356139A4 (en) | LIGURE COMBINED POLYPEPTIDES | |
| EP2370458A4 (en) | NEUREGULIN PEPTIDES AND THEIR USE | |
| CO6491031A2 (es) | Proteinas de fusion actriib-fc truncadas | |
| BRPI0822989A2 (pt) | anticorpos de neutralização de citomegalovíorus humano e uso dos mesmos | |
| EP2614072A4 (en) | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS | |
| IL208979B (en) | Humanized antibodies against human interferon-alpha | |
| EP2350286A4 (en) | PREPARATION OF RECOMBINANT NELL PROTEINS | |
| EP2276499A4 (en) | ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED | |
| PL2349314T3 (pl) | Formulacje liofilizowanego rekombinowanego VWF | |
| EP2382734A4 (en) | VERIFICATION OF SOFTWARE APPLICATIONS | |
| EP2207803A4 (en) | Cd9-specific human antibodies | |
| DK2260873T3 (da) | Pcylering af proteiner | |
| EP2303913A4 (en) | CRECL TARGET PEPTIDES | |
| IL222015B (en) | Humanized il-25 antibodies | |
| IL223665B (en) | Human antibodies to human cytomegalovirus gb (cmv) protein | |
| EP2462237A4 (en) | METHOD FOR IMPROVING THE EXPRESSION OF RECOMBINANT PROTEINS | |
| DK2154149T3 (da) | En trunkeret l1-protein af human papillomavirus 6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014. |